E4/DRSP, a Novel Combined Oral Contraceptive, submitted to Brazilian regulatory authorities

Liege, Belgium, 17 November 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the regulatory submission for E4/DRSP, a combined oral contraceptive containing estetrol (E4) and drospirenone (DRSP), has been submitted to the National Sanitary Surveillance Agency (ANVISA) by Mithra’s commercial partner, Libbs, the Women’s Health leader in Brazil.